Clariane SE (CHIX:CLARIP) 1-Year Sharpe Ratio: -0.66 (As of Jul. 19, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CHIX:CLARIP Clariane SE CHIX:CLARIP
62 GF Score
Price €4.13
GF Value €2.47
Valuation Significantly Overvalued
! 9 Warning Signs
View Full Analysis

What is Clariane SE 1-Year Sharpe Ratio?

Clariane SE CHIX:CLARIP 62 1-Year Sharpe Ratio is -0.66 as of Jul. 19, 2026. GuruFocus rates CHIX:CLARIP with a GF Score™ of 62/100 and a GF Value™ of €2.47 (Significantly Overvalued). The stock has 9 warning signs investors should review.

The 1-Year Sharpe Ratio measures the additional return that an investor receives per unit of increase in risk over the past year. As of today (2026-07-19), Clariane SE's 1-Year Sharpe Ratio is -0.66.

Clariane SE  (CHIX:CLARIp) 1-Year Sharpe Ratio Explanation

The 1-Year Sharpe Ratio inidicates the risk-adjusted return of an investment over the past year. It is calculated as the annualized result of the average monthly excess return divided by its standard deviation over the past year. The monthly excess return is the monthly investment return minus the monthly risk-free rate (typically the 10-year Treasury Constant Maturity Rate). If the risk-free rate for a specific region is not available, U.S. data is used by default.

The greater a portfolio's Sharpe Ratio, the better its risk-adjusted performance. A negative Sharpe Ratio means the risk-free rate is greater than the portfolio’s historical or projected return, or else the portfolio's return is expected to be negative.

Clariane SE 1-Year Sharpe Ratio Related Terms

CHIX:CLARIP vs HCA, THC, DVA: 1-Year Sharpe Ratio Comparison

For the Medical Care Facilities subindustry, Clariane SE's 1-Year Sharpe Ratio, along with its competitors' market caps and 1-Year Sharpe Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Clariane SE 1-Year Sharpe Ratio vs Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Clariane SE's 1-Year Sharpe Ratio distribution charts can be found below:

* The bar in red indicates where Clariane SE's 1-Year Sharpe Ratio falls into.


CHIX:CLARIP
62GF Score
Clariane SE CHIX:CLARIP
1-Year Sharpe Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Clariane SE 1-Year Sharpe Ratio Calculation

The 1-Year Sharpe Ratio measures the performance of an investment such as a stock or portfolio compared to a risk-free asset. A stock / portfolio's 1-Year Sharpe Ratio can be calculated by dividing the difference between the one-year returns of the investment and the risk-free rate, by the standard deviation of the investment returns over one year.

Frequently Asked Questions Learn more about 1-Year Sharpe Ratio →
What does a 1-Year Sharpe Ratio of -0.66 mean?
Clariane SE (CHIX:CLARIP) has a 1-Year Sharpe Ratio of -0.66 as of Jul. 19, 2026. 1-Year Sharpe Ratio measures the additional return that an investor receives per unit of increase in risk. View historical data for Clariane SE and its competitors.
Is Clariane SE's 1-Year Sharpe Ratio too high?
Clariane SE's current 1-Year Sharpe Ratio is -0.66. Overall, Clariane SE has a GF Score™ of 62/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Clariane SE's 1-Year Sharpe Ratio compare to HCA and THC?
Clariane SE's 1-Year Sharpe Ratio of -0.66 can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 1-Year Sharpe Ratio for a Healthcare Providers & Services company?
A good 1-Year Sharpe Ratio depends on the Healthcare Providers & Services industry context. However, 1-Year Sharpe Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 1-Year Sharpe Ratio mean?
A high 1-Year Sharpe Ratio can signal that a stock is expensive relative to its fundamentals. 1-Year Sharpe Ratio measures the additional return that an investor receives per unit of increase in risk. View historical data for Clariane SE and its competitors. Clariane SE's current 1-Year Sharpe Ratio is -0.66. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Clariane SE stock overvalued right now?
Based on GuruFocus' analysis, Clariane SE (CHIX:CLARIP) is currently considered Significantly Overvalued. The stock's GF Value™ is €2.47, compared to a current price of €4.13 — trading 67% above its estimated fair value. The current 1-Year Sharpe Ratio is -0.66. Clariane SE's overall GF Score™ is 62/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 1-Year Sharpe Ratio calculated?
1-Year Sharpe Ratio is calculated from a company's financial statements. For Clariane SE (CHIX:CLARIP), the current 1-Year Sharpe Ratio is -0.66 as of Jul. 19, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Clariane SE (CHIX:CLARIP) Overvalued in 2026?

Based on GuruFocus' analysis, Clariane SE stock appears to be overvalued. The current stock price of €4.13 is trading 67% above its estimated GF Value™ of €2.47. GuruFocus considers Clariane SE to be Significantly Overvalued.

Key valuation signals for CHIX:CLARIP:

  • 1-Year Sharpe Ratio: -0.66
  • GF Value™: €2.47 vs. price of €4.13 (67% above fair value)
  • GF Score™: 62/100 with 9 warning signs

No single metric tells the full story. See the CHIX:CLARIP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Clariane SE Business Description

Address 21-25, Rue Balzac, Paris, FRA, 75008
Clariane SE is a specialist in non-acute care and operates in two main areas: long-term care, through two forms of support, medicalized nursing homes offering specialty facilities accommodation and care for vulnerable older people and alternative living solutions, and specialty care activities such as specialty and post-acute , mental health and a number of medical, surgical and obstetrics clinics. Its segments include France, Germany, Benelux, Italy and Spain.
62GF Score

Get the complete analysis for CHIX:CLARIP

1-Year Sharpe Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€4.13
Price
€2.47
GF Value